We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-23.53%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$142M
Cap. Flow
-$50.1M
Cap. Flow %
-27.76%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$45.2M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$4.71M
3
PHVS icon
Pharvaris
PHVS
+$160K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
1
DELISTED
Ventyx Biosciences
VTYX
$77M 42.68%
2,298,833
-1,162,703
-34% -$45.2M
ALXO icon
2
ALX Oncology
ALXO
$278M
$43.8M 24.3%
9,699,925
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.46B
$33.8M 18.74%
1,035,396
– –
PHVS icon
4
Pharvaris
PHVS
$2.47B
$18.4M 10.17%
2,278,575
-18,135
-0.8% -$160K
IMPL
5
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$3.86M 2.14%
2,759,791
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$3.55M 1.97%
1,866,339
– –
CINC
7
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-383,390
Closed -$4.71M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q1 2023 Portfolio in Review

As of Q1 2023, venBio Partners held 7 positions worth $180M, down 44% from $323M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $50.1M in Q1 2023, closing 1 position and reducing 2 holdings. Its most notable exit was CinCor Pharma, Inc. Common Stock, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q1 2023 reduction was Ventyx Biosciences, cutting an estimated $45.2M.
  • venBio Partners fully exited CinCor Pharma, Inc. Common Stock in Q1 2023, selling an estimated $4.71M.
  • venBio Partners's ten largest holdings make up 100% of its $180M portfolio in Q1 2023.
  • venBio Partners opened 0 new positions and closed 1 in Q1 2023.
  • venBio Partners's portfolio value fell 44% quarter-over-quarter to $180M.

Based on venBio Partners's 13F filing for Q1 2023, filed 15 May 2023.